<?xml version="1.0" encoding="utf-8"?>
<recommendedContent xmlns="http://api.mspoke.com">
    <recommendedItem id="20100101_19_407"
                     title="ICU Catheter Infections Can Be Virtually Eliminated (CME/CE)"
                     score="0.014"
                     href="http://www.medpagetoday.com/CriticalCare/InfectionControl/tb/18308?impressionId=1265728241710"
                     
      Catheter-related infections aren&apos;t inevitable in the ICU, according to a quality initiative that maintained rates at nearly zero for three years in Michigan hospitals.&lt;br&gt;
&lt;br&gt;The maintenance phase, after initial implementation of low-tech measures such as handwashing and removal of unneeded catheters, saw no rebound in catheter-related infections, Peter J. Pronovost, MD, PhD, of Johns Hopkins, and colleagues reported online in &lt;em&gt;BMJ&lt;/em&gt;.&lt;br&gt;
&lt;br&gt;The first 18 months of their &lt;a href=&quot;http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/4771&quot; mce_href=&quot;http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/4771&quot; target=&quot;_blank&quot;&gt;Keystone ICU initiative&lt;/a&gt; dropped catheter-related interventions from a mean of 7.7 and median of 2.2 per 1,000 catheter days down to 1.3 and 0, respectively.&lt;br&gt;
&lt;br&gt;At the 36 month mark, infection rates remained almost nil, at a mean of 1.1 and median of 0 per 1,000 catheter days.&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&quot;For the most part, hospitals view these infections as inevitable, as the cost of doing business, that patients are too sick, that these can&apos;t be prevented,&quot; Pronovost told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;That&apos;s just not true.&quot;&lt;/p&gt;
&lt;p&gt;Catheter-related infections are the number one cause of preventable death in hospitals and ICUs, ahead of even ventilator-related pneumonia, he noted.&lt;/p&gt;
&lt;p&gt;The changes seen at the 90 Michigan ICUs that stayed with the catheter-related infection initiative were impressive, representing one of the largest and longest improvements the field has seen.&lt;/p&gt;
&lt;p&gt;Often, quality initiatives fail on durability after the study funding and resources disappear, and hospitals are left on their own, Pronovost noted.&lt;/p&gt;
&lt;p&gt;&quot;If you push you might get some effect, but then you stop pushing  --  in other words the external control goes away  --  and the performance goes right back down,&quot; he said in an interview. &quot;It can&apos;t just be the stick that drives it.&quot;&lt;/p&gt;
&lt;p&gt;The intervention started with 103 ICUs that implemented strategies to reduce rates of catheter-related bloodstream infections rates over 18 months, with measurement and feedback of infection rates.&lt;/p&gt;
&lt;p&gt;The strategies aimed at improving execution of five evidence-based recommendations, as follows: &lt;ul&gt; &lt;li&gt;Hand washing before insertion of the catheter&lt;/li&gt; &lt;li&gt;Using gowns and full barrier precautions at catheter insertion&lt;/li&gt; &lt;li&gt;Cleaning the skin with chlorhexidine before catheter insertion&lt;/li&gt; &lt;li&gt;Avoiding the femoral site when possible&lt;/li&gt; &lt;li&gt;Removing unnecessary catheters&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Then, over the subsequent 18-month maintenance period, ICU teams were instructed to integrate this intervention into staff orientation, to collect monthly data from hospital infection control staff, and to report infection rates to physicians and others.&lt;/p&gt;
&lt;p&gt;Along with the sustained reduction in overall catheter-related infections, the researchers found a prolonged reduction in bloodstream infections that was significant during all study periods, compared to baseline.&lt;/p&gt;
&lt;p&gt;Rates decreased from a mean of 7.7 and median 2.7 of per 1,000 catheter days at baseline to 1.3 and 0, respectively, at 16 to 18 months after implementation. They remained at 1.1 and 0 at months 34 to 36 (-1% versus 18 months, 95% CI -9% to +7%).&lt;/p&gt;
&lt;p&gt;ICU teams interviewed attributed the continuously low rates to five factors: &lt;ul&gt; &lt;li&gt;Continued feedback on infection data&lt;/li&gt; &lt;li&gt;Improvements in safety culture as part of the project&lt;/li&gt; &lt;li&gt;An &quot;unremitting belief in the preventability of bloodstream infections&quot;&lt;/li&gt; &lt;li&gt;Involvement of senior leaders&lt;/li&gt; &lt;li&gt;A noncompetitive, shared goal to reduce infection rates throughout the state&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Of these, Pronovost called culture change in the ICUs the key factor to sustainability, although the researchers cautioned that which aspects contributed were not formally evaluated.&lt;/p&gt;
&lt;p&gt;They said they could not determine the impact incentive payments from Blue Cross Blue Shield of Michigan to hospitals that continued their participation  --  payments that were based on performance thresholds in subsequent years.&lt;/p&gt;
&lt;p&gt;Pronovost&apos;s team is now working to implement the quality initiative state-by-state nationwide, supported by the Agency for Healthcare Research and Technology.&lt;/p&gt;
&lt;p&gt;&quot;It seems absurd that this wouldn&apos;t be in every hospital in the country,&quot; he said in an interview. &quot;It&apos;s worked on a large scale, it&apos;s exceedingly cheap, there&apos;s no fancy technology.&quot;&lt;/p&gt;
&lt;p&gt;Success isn&apos;t only for community hospitals, Pronovost emphasized.&lt;/p&gt;
&lt;p&gt;Large, often academic, medical centers frequently express the conviction that their sicker, more complex ICU population wouldn&apos;t produce the same results, that their infections truly are inevitable, he said.&lt;/p&gt;
&lt;p&gt;&quot;To them I say, Not so,&quot; he told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;We have shown at Johns Hopkins, at the University of Michigan, at Pittsburgh, using a similar but different approach, at Tufts  --  many large academic medical centers have had dramatic reductions of these infections.&quot;&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The project was supported, for the period from October 2003 to September 2005, by the Agency for Healthcare Research and Quality and the Michigan Health &amp;amp; Hospital Association.&lt;/p&gt;&lt;p&gt;Pronovost and a co-author reported receiving received lecture fees from various healthcare organizations and grant support from the Agency for Healthcare Research and Quality, the Robert Wood Johnson Foundation, the National Patient Safety Agency, and the World Health Organization to study and improve quality of care, including catheter-related bloodstream infections.&lt;/p&gt;&lt;p&gt;Co-authors reported conflicts of interest with government agencies, Cubist, Astellas, Merck, Forrest, Cadence, the Robert Wood Johnson Foundation, Lilly, Edward Life Sciences, and Sage.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_301"
                     title="Tight Glucose Control Fails in Septic Shock (CME/CE)"
                     score="0.005"
                     href="http://www.medpagetoday.com/CriticalCare/Sepsis/tb/18160?impressionId=1265728241710"
                     
      Septic shock patients treated with a corticosteroid get no survival advantage from tight glucose control or addition of a second corticosteroid to provide more mineralocorticoid activity, according to results of a randomized trial.&lt;br&gt;
&lt;br&gt;Aiming for normoglycemia at 80 to 110 mg/dL rather than the standard 150 mg/dL had no impact on inhospital mortality rates (45.9% versus 42.9%, &lt;em&gt;P&lt;/em&gt;=0.50), Djillali Annane, MD, of H&amp;#244;pital Raymond Poincar&amp;#233; in Garches, France, and colleagues found.&lt;br&gt;
&lt;br&gt;Inhospital mortality was likewise similar whether patients got hydrocortisone (Solu-Cortef) alone or with the addition of fludrocortisone ([Florinef] 42.9% versus 45.8%, &lt;em&gt;P&lt;/em&gt;=0.50), they reported in the Jan. 27 issue of the &lt;em&gt;Journal of the American Medical Association&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;This aggressive treatment strategy should not be routine, the researchers recommended.&lt;/p&gt;
&lt;p&gt;These findings largely match the general lack of benefit seen with tight glycemic control in recent studies with ICU patients overall.&lt;/p&gt;
&lt;p&gt;The prematurely terminated &lt;a href=&quot;http://www.medpagetoday.com/MeetingCoverage/SCCM/5096&quot; mce_href=&quot;http://www.medpagetoday.com/MeetingCoverage/SCCM/5096&quot; target=&quot;_blank&quot;&gt;European Glucontrol Trial&lt;/a&gt; found no mortality benefit but a seven-fold higher risk of hypoglycemia with an 80 to 110 mg/dL target in the ICU.&lt;/p&gt;
&lt;p&gt;In the &lt;a href=&quot;http://www.medpagetoday.com/CriticalCare/Intensivists/13397&quot; mce_href=&quot;http://www.medpagetoday.com/CriticalCare/Intensivists/13397&quot; target=&quot;_blank&quot;&gt;NICE-SUGAR&lt;/a&gt; study, 90-day mortality was actually higher in the tight glucose control group (27.9% versus 24.9%, &lt;em&gt;P&lt;/em&gt;=0.02), although there was a trend for benefit in patients who got corticosteroids (&lt;em&gt;P&lt;/em&gt;=0.06).&lt;/p&gt;
&lt;p&gt;Glucose targets are being re-evaluated across medicine as the &quot;lower is better&quot; paradigm has had a safety asterisk added everywhere from diabetes care to the ICU, noted Richard Bergenstal, MD, American Diabetes Association president for medicine and science.&lt;/p&gt;
&lt;p&gt;&quot;All of a sudden it&apos;s becoming more than a single number,&quot; he told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;Now be it inpatient or outpatient, we&apos;re realizing that ... you have to do it while you&apos;re minimizing hypoglycemia.&quot;&lt;/p&gt;
&lt;p&gt;A more nuanced and &lt;a href=&quot;http://www.medpagetoday.com/Cardiology/Diabetes/13818&quot; mce_href=&quot;http://www.medpagetoday.com/Cardiology/Diabetes/13818&quot; target=&quot;_blank&quot;&gt;individualized&lt;/a&gt; strategy is prudent, Bergenstal agreed.&lt;/p&gt;
&lt;p&gt;The current clinical uncertainty underscores the need for large-scale international cooperation to get adequately powered trials, according to an accompanying editorial.&lt;/p&gt;
&lt;p&gt;In it, Greet Van den Berghe, MD, PhD, of the Catholic University of Leuven, Belgium, cautioned that Annane&apos;s Corticosteroids and Intensive Insulin Therapy for Septic Shock (COIITSS) study was grossly underpowered.&lt;/p&gt;
&lt;p&gt;The initial studies that led to rapid adoption of intensive insulin therapy in ICUs around the world had suggested an absolute reduction in mortality of only 3%, whereas the COIITSS study projected a 12.5% absolute benefit.&lt;/p&gt;
&lt;p&gt;More importantly, the study achieved mean glucose levels of only between 120 and 130 mg/dL in the intervention group for whom the aim was 80 to 110 mg/dL, which resulted in considerable overlap with the standard care group for whom mean levels were about 145 mg/dL.&lt;/p&gt;
&lt;p&gt;This could account for the lack of difference in outcome, Van den Berghe said.&lt;/p&gt;
&lt;p&gt;But the intensive insulin group did have &quot;markedly&quot; lower blood glucose levels for the duration of their ICU stay and spent more time in the 80 to 110 mg/dL range compared with the standard care group (both &lt;em&gt;P&lt;/em&gt;&amp;lt;0.00001), the researchers noted.&lt;/p&gt;
&lt;p&gt;Because corticosteroids further aggravate the &quot;diabetes of injury&quot; seen with septic shock, Annane&apos;s group undertook a multicenter trial of 509 adults treated for septic shock with multiple organ dysfunction over a three year period at 11 ICUs in France.&lt;/p&gt;
&lt;p&gt;Patients were randomly assigned to tight glucose control using continuous intravenous insulin infusion to target a glucose level of 80 to 110 mg/dL or conventional insulin therapy targeted to guidelines-recommended 150 mg/dL or under. They were additionally randomized to receive hydrocortisone alone (50-mg bolus every six hours) or in combination with fludrocortisone (50-&amp;#956;g tablets once daily) for seven days.&lt;/p&gt;
&lt;p&gt;Aside from the lack of inhospital mortality advantage, tight glucose control also failed to produce a benefit for the following secondary endpoints: &lt;ul&gt; &lt;li&gt;Overall survival (hazard ratio 1.04, &lt;em&gt;P&lt;/em&gt;=0.78) &lt;/li&gt; &lt;li&gt; ICU length of stay for survivors (median 10 versus nine days, &lt;em&gt;P&lt;/em&gt;=0.68)&lt;/li&gt; &lt;li&gt;Duration of hospital stay overall (24 versus 22 days, &lt;em&gt;P&lt;/em&gt;=0.87)&lt;/li&gt; &lt;li&gt;Median vasopressor-free days (four for both, P=0.58)&lt;/li&gt; &lt;li&gt;Median mechanical ventilation-free days (10 versus 13, &lt;em&gt;P&lt;/em&gt;=0.51)&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Nor was there evidence for interaction with fludrocortisone in the primary endpoint (relative risk 0.89 versus 0.91 hydrocortisone alone, &lt;em&gt;P&lt;/em&gt;=0.31) or benefit in any other endpoint.&lt;/p&gt;
&lt;p&gt;The one effect of intensive insulin appeared to be an increase in episodes of severe hypoglycemia, defined by glucose falling below 40 mg/dL (mean 0.29 versus 0.14 episodes per patient, &lt;em&gt;P&lt;/em&gt;=0.003).&lt;/p&gt;
&lt;p&gt;However, having hypoglycemia did not increase the risk of death in intervention group patients compared with controls (45.2% versus 50%).&lt;/p&gt;
&lt;p&gt;The researchers cautioned that the study did not rule out a benefit from some degree of glucose control compared with none.&lt;/p&gt;
&lt;p&gt;They also noted that healthcare providers were not blinded to administration of fludrocortisone, for which no placebo was available.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was funded by the Assistance Publique&amp;#8211;H&amp;#244;pitaux de Paris. The researchers reported no conflicts of interest.&lt;/p&gt;&lt;p&gt;Van den Berghe, through the Catholic University of Leuven, reported receiving structural research financing from the Methusalem program, funded by the Flemish government.&lt;/p&gt;&lt;p&gt;Bergenstal reported receiving research funding and serving on advisory boards for various pharmaceutical companies related to novel diabetes drugs but without any personal financial compensation.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_255"
                     title="Biomarker Guideline Reduced Antibiotic Use (CME/CE)"
                     score="0.001"
                     href="http://www.medpagetoday.com/HospitalBasedMedicine/InfectionControl/tb/18114?impressionId=1265728241710"
                     
      &lt;p&gt;A biomarker-guided strategy for antibiotics in intensive care units reduced drug use without increasing mortality, French researchers said.&lt;/p&gt;
&lt;p&gt;In a randomized, open-label study, the biomarker procalcitonin allowed physicians to reduce the quantity of antibiotics they prescribed, according to Michel Wolff, MD, of H&amp;#244;pital Bichat-Claude-Bernard in Paris, and colleagues.&lt;/p&gt;
&lt;p&gt;In principle, the approach could slow the emergence of antibiotic resistance, Wolff and colleagues concluded online in &lt;em&gt;The Lancet&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;Procalcitonin is thought to be a &quot;fairly specific marker for severe bacterial infection in patients with suspected sepsis,&quot; the researchers noted in the journal.&lt;/p&gt;
&lt;p&gt;As well, serum procalcitonin concentrations have been shown to be a useful guide to reducing antibiotic use in patients with lower-respiratory-tract infections, they said.&lt;/p&gt;
&lt;p&gt;But the value of the biomarker in reducing inappropriate antibiotic use has not been shown in all intensive care patients, they said. To fill the gap, they conducted a prospective study of 630 patients in eight French ICUs.&lt;/p&gt;
&lt;p&gt;Patients were randomly assigned to be treated according to usual antibiotic protocols or to have their therapy guided by procalcitonin levels.&lt;/p&gt;
&lt;p&gt;For patients in the procalcitonin group, doctors were encouraged to start antibiotics at inclusion if the levels were 0.5 micrograms per liter or greater. Otherwise, they were discouraged from doing so.&lt;/p&gt;
&lt;p&gt;They were also encouraged to stop antibiotics, once started, if the procalcitonin concentration fell by 80% or more from its peak, or if the concentration was below 0.5 micrograms per liter.&lt;/p&gt;
&lt;p&gt;The primary endpoints were death from any cause at 28 and 60 days and differences in antibiotic use.&lt;/p&gt;
&lt;p&gt;The researchers reported: &lt;ul&gt; &lt;li&gt;At 30 days, mortality in the procalcitonin group was 21.2%, compared with 20.4% in the control group, for an absolute difference of 0.8%. That was well below the pre-set 10% difference for non-inferiority.&lt;/li&gt; &lt;li&gt;At 60 days, the comparable figures were 30% and 26.1%, for an absolute difference of 3.8%, which also established non-inferiority.&lt;/li&gt; &lt;li&gt;Patients in the procalcitonin group had 14.3 days without antibiotics, on average, compared with 11.6 days in the control group. The absolute difference of 2.7 days was significant at &lt;em&gt;P&lt;/em&gt;&amp;lt;0.0001.&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;The researchers cited a number of limitations, including the open design, which might have permitted bias, and a low number of surgical patients, which may limit how widely the findings can be applied.&lt;/p&gt;
&lt;p&gt;As well, they noted, 53% of patients in the procalcitonin group did not get therapy guided by the study protocol. Despite that, Wolff and colleagues said, the results remained statistically significant if those patients were excluded.&lt;/p&gt;
&lt;p&gt;Various studies have shown that it&apos;s possible to curtail unnecessary antibiotic use in hospitals, according to Marin Kollef, MD, of Washington University School of Medicine in St Louis.&lt;/p&gt;
&lt;p&gt;But because of the limitations of the French study, it remains unclear whether using procalcitonin is the best approach, he wrote in an accompanying editorial.&lt;/p&gt;
&lt;p&gt;&quot;Whether the ideal strategy involves the use of a serum marker such as procalcitonin or a locally applied practice protocol remains to be established,&quot; Kollef concluded.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was supported by the Assistance Publique-H&amp;#244;pitaux de Paris, France, and Brahms, Germany. Wolff reported financial links with Merck Sharp &amp;amp; Dohme-Chibret, Janssen-Cilag, Gilead, and AstraZeneca.&lt;/p&gt;&lt;p&gt;Kollef reported no conflicts.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20090101_19_2929"
                     title="ICAAC: Surgical Masks Don&apos;t Prevent Infection (CME/CE)"
                     score="-0.005"
                     href="http://www.medpagetoday.com/MeetingCoverage/ICAAC/tb/16006?impressionId=1265728241710"
                     
      &lt;p&gt;SAN FRANCISCO  --  Used consistently, N95 respirator masks prevented 75% of respiratory infections for high-risk healthcare workers, but regular surgical masks didn&apos;t appear to be effective against respiratory infections at all, researchers reported here.&lt;/p&gt;
&lt;p&gt;In the first randomized trial of their efficacy, the N95 masks worked regardless of whether seal against the skin (a &quot;fit test&quot;) was confirmed, according to investigators at the Interscience Conference on Antimicrobial Agents and Chemotherapy.&lt;/p&gt;
&lt;p&gt;The findings supported the Institute of Medicine&apos;s recommendation for N95 respirators to prevent spread of H1N1 in healthcare settings.&lt;/p&gt;
&lt;p&gt;Although surgical masks were the face of the 2003 SARS epidemic in Asia, they don&apos;t protect against pandemic H1N1 (swine flu) or any other respiratory infection, C. Raina MacIntyre, MBBS, PhD, of the University of New South Wales in Sydney, Australia, and colleagues warned.&lt;/p&gt;
&lt;p&gt;Last month, MacIntyre presented a preliminary version of these findings to an &lt;a href=&quot;http://www.medpagetoday.com/HospitalBasedMedicine/WorkForce/15518&quot; target=&quot;_blank&quot;&gt;Institute of Medicine panel&lt;/a&gt; deliberating guidelines for personal protective equipment standards for healthcare workers. Aside from her trial, there was little but anecdotal testimony.&lt;/p&gt;
&lt;p&gt;&quot;There are many guidelines -- quite sweeping guidelines -- about the use of masks without really a shred of high-level evidence to support them,&quot; said MacIntyre. &quot;Until recently, the only data supporting mask use are retrospective, observational data from outbreaks such as SARS.&quot;&lt;/p&gt;
&lt;p&gt;Confirmation of surgical masks&apos; failure came as no surprise to Frank Lowy, MD, of Columbia University, who was not involved in the study.&lt;/p&gt;
&lt;p&gt;He noted that unlike surgical masks, N95 respirators are made of material certified to block 95% of particles 0.3 microns or larger in diameter and can be fit tested to seal around the nose and mouth.&lt;/p&gt;
&lt;p&gt;However, he said he was surprised by the similarity of outcomes whether or not N95 respirators were fit tested, as recommended.&lt;/p&gt;
&lt;p&gt;If anything, the non-fit tested respirators appeared slightly more effective against clinical respiratory illness compared with controls (RR 0.36, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001) and surgical masks (RR 0.49, &lt;em&gt;P&lt;/em&gt;=0.014) than were fit tested respirators (RR 0.5, &lt;em&gt;P&lt;/em&gt;=0.005, and RR 0.67, &lt;em&gt;P&lt;/em&gt;=0.151, respectively).&lt;/p&gt;
&lt;p&gt;&quot;It&apos;s very time consuming and labor intensive to get hospital employees fit tested,&quot; Lowy said. &quot;So if you don&apos;t have to do that, that&apos;s a considerable saving in time, effort, and expense.&quot;&lt;/p&gt;
&lt;p&gt;The researchers still recommended fit testing as the standard for practice.&lt;/p&gt;
&lt;p&gt;Moreover, American hospitals could face problems if they don&apos;t follow that guidance, since the Occupational Safety and Health Administration (OSHA) still requires testing for air leakage into the respirators, John S. Adams, MD, of Knoxville (Tenn.) Infectious Disease Consultants noted during a question-and-answer session after the late-breaking presentation.&lt;/p&gt;
&lt;p&gt;The trial included 1,936 emergency and respiratory ward nurses and physicians at 24 hospitals in Beijing during the winter cold and flu season. They were cluster-randomized to wear surgical masks (3M brand), fit-tested N95 respirators (3M brand), or non-fit tested N95 respirators during all work hours for four consecutive weeks. They were followed for an additional week off randomization.&lt;/p&gt;
&lt;p&gt;Because the culture of mask use was so prevalent in China, the control group consisted of participants following usual practice at nine hospitals, though the researchers selected out centers with relatively low mask use for further analysis.&lt;/p&gt;
&lt;p&gt;Consistent surgical mask use was no better than controls for prevention of clinical respiratory illness (6.7% versus 9.2%, &lt;em&gt;P&lt;/em&gt;=0.159) or of influenza-like illness (0.6% versus 1.3%, &lt;em&gt;P&lt;/em&gt;=0.336).&lt;/p&gt;
&lt;p&gt;But compared with controls, N95 respirators together reduced the rate of clinical respiratory illness 60% (3.9% versus 9.2%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001) and the rate of influenza-like illness by 75% (0.36% versus 1.3%, &lt;em&gt;P&lt;/em&gt;=0.035).&lt;/p&gt;
&lt;p&gt;The advantage of N95 respirators was substantial compared with surgical masks (RR 0.58 for clinical respiratory illness, &lt;em&gt;P&lt;/em&gt;=0.019).&lt;/p&gt;
&lt;p&gt;Adjustment for differences between hospitals in the level of handwashing, vaccination, and other factors that would impact infection risk only increased the apparent effectiveness of the N95 in staving off influenza to 96% (OR 0.04, 95% CI 0.01 to 0.15).&lt;/p&gt;
&lt;p&gt;Although the study could not rule out a small degree of efficacy for surgical masks that could be enough for the low-exposure general public, MacIntyre said masks can&apos;t be recommended to protect healthcare workers.&lt;/p&gt;
&lt;p&gt;&quot;Given the importance of protecting frontline workers and the need to maintain essential public services during a pandemic, I feel it places healthcare workers at unacceptable risk to recommend they wear a surgical mask,&quot; she said. &quot;You might as well tell them to wear nothing.&quot;&lt;/p&gt;
&lt;p&gt;Her group noted that the study was limited by use of convenience controls, though use of cloth masks by some controls would only have biased the results toward no effect. &lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was funded by the University of New South Wales in collaboration with Beijing CDC and Westmead Hospital. 3M China, which makes a N95 respirator, provided in-kind support by assisting with fit-test training of study staff.&lt;/p&gt;&lt;p&gt;MacIntyre reported receiving funding for other, unrelated, investigator-driven studies from GlaxoSmithKline, CSL Biotherapies, and Wyeth and having been an investigator on a Merck clinical trial.&lt;/p&gt;&lt;p&gt;Lowy reported no relevant conflicts of interest. Adams reported no conflicts of interest.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_121"
                     title="SCCM: Teamwork Cuts ICU Pneumonia (CME/CE)"
                     score="-0.005"
                     href="http://www.medpagetoday.com/MeetingCoverage/SCCM/tb/17934?impressionId=1265728241710"
                     
      &lt;p&gt;MIAMI BEACH  --  A coordinated effort among physicians, nurses, therapists, and other intensive care staff produced a dramatic reduction in the incidence of ventilator-associated pneumonia at a Tennessee hospital, according to a study reported here.&lt;/p&gt;
&lt;p&gt;Researchers told attendees at the annual meeting of the Society of Critical Care Medicine that nosocomial pneumonia cases decreased from 34 episodes in one 12-month period to four in the most recent year  --  including a 10-month period when no cases of ventilator-associated pneumonia were reported.&lt;/p&gt;
&lt;p&gt;&quot;The use of a collaborative team approach, daily multidisciplinary rounds, and implementation of a ventilator-acquired pneumonia protocol has led to ventilator-acquired pneumonia reductions while improving patient care and outcomes,&quot; said Lisa Boghozian, MSN, RN, a clinical nurse specialist at Johnson City Medical Center.&lt;/p&gt;
&lt;p&gt;&quot;We learned to work together,&quot; she said at a poster presentation. &quot;We learned to share jobs and to make sure the patients received the protocol-required treatment. But the success of these programs may have to be nurse-driven.&quot;&lt;/p&gt;
&lt;p&gt;By cutting the incidence of ventilator-associated pneumonia by 88%, the effort reduced ICU intensive care unit expenses by $2.2 million and overall hospital expenses by $9 million, according to Pamela Ditto, MBA, RRT, a respiratory therapist and the team&apos;s record keeper.&lt;/p&gt;
&lt;p&gt;She said that the reduction in ventilator-associated pneumonia cases resulted in avoiding 2,470 days in the intensive care unit and 207 days on ventilation.&lt;/p&gt;
&lt;p&gt;&quot;We educated our staff that the six components of ventilator-acquired pneumonia prevention had to be performed every day on every shift,&quot; she said.&lt;/p&gt;
&lt;p&gt;The protocol requires: &lt;ul&gt; &lt;li&gt;Keeping the patient&apos;s head raised 30&amp;#176;&lt;/li&gt; 
&lt;li&gt;Performing oral hygiene&lt;/li&gt; 
&lt;li&gt;Performing deep vein thrombosis prophylaxis&lt;/li&gt; 
&lt;li&gt;Performing gastrointestinal prophylaxis to prevent reflux&lt;/li&gt; 
&lt;li&gt;Regularly assessing the ability to wean patients from the ventilator&lt;/li&gt; 
&lt;li&gt;Giving adequately sedated patients vacations from sedation&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;In the year before the study period  --  when the hospital counted 34 cases of ventilator-associated pneumonia  --  Boghozian said it seemed that the staff simply accepted that there would be cases and there wasn&apos;t a concentrated effort to control the occurrence.&lt;/p&gt;
&lt;p&gt;The four cases of ventilator-associated pneumonia in the year ending in June 2009 all occurred in April  --  after 10 consecutive months without a single case. &quot;We might have become complacent,&quot; she speculated, but she also noted that during that period the hospital cared for several trauma cases that included patients with facial injuries that might have prevented careful oral hygiene known to be a major factor in ventilator-associated pneumonia.&lt;/p&gt;
&lt;p&gt;&quot;Prevention of ventilator-acquired pneumonia and other nosocomial infections are the types of things that healthcare providers will be looking at to improve conditions for patients and to cut costs,&quot; Ditto said.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;Neither Boghozian nor Ditto had relevant financial disclosures.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
</recommendedContent>